Sector consensus Monte Rosa Therapeutics, Inc.
Stocks
GLUE
US61225M1027
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.38 USD | -6.90% |
|
-31.83% | -1.91% |
| 07-31 | Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial | MT |
| 07-31 | Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 30.67 | +99.39% | 6 | ||||||
| 680.7 | +21.51% | 23 | ||||||
| 207 | +13.46% | 21 | ||||||
| 275.17 | +17.92% | 18 | ||||||
| 415.64 | +32.47% | 27 | ||||||
| 264,708.89 | +45.28% | 24 | ||||||
| 581.83 | +1.49% | 12 | ||||||
| 267.65 | +26.5% | 18 | ||||||
| 72.53 | +7.07% | 14 | ||||||
| 185.56 | +17.14% | 16 | ||||||
| 69.73 | -3.34% | 11 | ||||||
| 228.5 | -1.03% | 14 | ||||||
| 138.56 | +29.14% | 6 | ||||||
| 130.53 | -2.67% | 12 | ||||||
| 37.73 | +4.6% | 11 | ||||||
| 133.31 | +0.78% | 13 | ||||||
| 89.33 | +63.94% | 21 | ||||||
| 610.05 | +99.68% | 19 | ||||||
| 44.07 | +4.11% | 14 | ||||||
| 127.18 | +26.79% | 22 | ||||||
| Average | 13,451.73 | +25.21% | 16 | ||||||
| Weighted average by Cap. | 22,764.9 | +21.97% | 19 |
- Stock Market
- Stocks
- GLUE Stock
- Sector Monte Rosa Therapeutics, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
